Selective inhibition of CBP/p300 HAT by A-485 results in suppression of lipogenesis and hepatic gluconeogenesis

Feiye Zhou1, Qianqian Liu1, Linlin Zhang1, Qin Zhu1, Shushu Wang1, Kecheng Zhu1, Ruyuan Deng2, Yun Liu1, Guoyue Yuan3, Xiaow Wang1 and Libin Zhou1

Abstract
The histone acetyltransferases CREB-binding protein (CBP) and its parologue p300 are transcriptional coactivators which are essential for a multitude of signaling pathways and energy homeostasis. However, the role of CBP/p300 HAT domain in regulating energy balance is still unclear. Here, C57BL/6 mice fed with either normal chow diet (NCD) or high-fat diet (HFD) were administrated with A-485, a recently reported selective inhibitor of CBP/p300 HAT activity for 1 week and the metabolic change was analyzed. The white adipose tissue (WAT) weight and adipocyte size were reduced in A-485-administrated mice, with decreased expressions of lipogenic genes and transcriptional factors. In the liver of A-485-treated mice, the lipid content and lipogenic gene expressions were lowered while the binding of forkhead box O1 (FOXO1) to glucose-6-phosphatase (G6Pc) promoter was reduced, leading to decreased expression of G6Pc. In primary mouse hepatocytes, A-485 abolished cAMP-elicited mRNA expressions of key gluconeogenic enzymes and promoted FOXO1 protein degradation via increasing its ubiquitination.
Thus, A-485 inhibits lipogenesis in WAT and liver as well as decreases hepatic glucose production via preventing FOXO1 acetylation, leading to its protein degradation through a proteasome-dependent pathway. The specific inhibition of CBP/p300 HAT will provide a novel therapeutic approach for metabolic diseases.

Introduction
Protein acetylation is a key post-translational modification (PTM) in cellular regulation. With advances in mass spectrometric technologies, both histone and non-histone have been proved to be targets of acetylation in nearly all intracellular compartments1,2. It has been demonstrated that protein acetylation may serve as a broad bridge between extracellular nutrient status and intracellular metabolic pathways in physiological and pathological processes2. Thus, control of acetylation has emerged as an attractive therapeutic strategy for several metabolic diseases3,4, which motivates intense drug discovery efforts in this area5. Previous researches have paid more attention to the effects of histone deacetylases on the regulation of energy homeostasis. However, the role of counter-regulators histone acetyltransferases (HATs) in metabolic processes is poorly understood.
As the KAT3 family of HATs6, CREB-binding protein (CBP) and p300 can acetylate lysine residues on histones to change chromatin structure and function, as well as lysine residues on nonhistone proteins to modulate their activities7. The early embryonic lethality observed in CBP/p300 knockout mice indicates the important role of CBP/p300 in normal development8,9. CBP and p300 are large proteins that contain several conserved domains, including NRIID, CH1 (TAZ1), KIX, Bromodomain, PHD, HAT, ZZ, TAZ2, and NCBD10. The domains of CBP/p300...
exhibit functional diversity by providing scaffolds for the interaction with their target regulators. HAT domain functions as an acetyllysine “writer” that acetylates target proteins and bromodomain functions as an acetyllysine “reader” that binds to target proteins. It is still unclear whether CBP/p300 HAT domain is important for whole animal energy homeostasis while KIX domain and CH1 domain have been reported to participate in metabolic control. It will be promising to develop a highly selective inhibitor of CBP/p300 HAT, so as to better understand the association of CBP/p300 HAT with overall metabolic signaling pathways.

Several HAT inhibitors are routinely used to probe epigenetic pathways, but most of them show poor selectivity in vitro. The most recently reported CBP/p300 HAT inhibitor A-485 represents a significant step forward in the development of HAT chemical probes. A-485 can inhibit the acetylation activity of both CBP and p300 and is at least 1000-fold more potent than previously described cell-permeable tool compounds. As a drug-like HAT inhibitor, A-485 inhibited proliferation in lineage-specific tumor types, including several hematological malignancies and androgen receptor-positive prostate cancer. It has been underscored for evaluating the clinical utility of A-485 in multiple human cancers, but its metabolic effect remains unclear. By giving mice 1 week administration of A-485, our study demonstrated in vivo metabolic effect of A-485 and provided insight into how CBP/p300 HAT maintained metabolic homeostasis, especially in white adipose tissue (WAT) and liver.

Material and methods

Animal experiment

Male C57BL/6 mice were purchased from Shanghai Slack Experimental Center. Mice were housed in a barrier facility with 12 h light/12 h dark cycles. The mice were intraperitoneally injected with A-485 (20 mg·kg⁻¹·day⁻¹) for 1 week under either normal chow diet (NCD) or high-fat diet (HFD) condition. All animal protocols were reviewed and approved by the Animal Care Committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine.

Lean and fat mass were determined via EchoMRI in live. For glucose tolerance test (GTT), mice were intraperitoneally injected with A-485 (20 mg·kg⁻¹·day⁻¹) for 16 h. For pyruvate tolerance test (PTT), mice were intraperitoneally injected with 2 g/kg body weight of pyruvate after 16 h fasting. For insulin tolerance test (ITT), mice were intraperitoneally injected with 0.75 UI/kg body weight of insulin after 6 h fasting.

Primary hepatocyte isolation and culture

Primary mouse hepatocytes were isolated from C57BL/6 mice by a two-step perfusion technique as described. Cells were treated with 100 μM 8-Bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP, Sigma), 3 μM A-485 (MedChemExpress), 10 μM MG132 (Beyotime Biotechnology), or 10 μg/ml cycloheximide (CHX, Sigma).

Primary white adipocyte differentiation

Stromal vascular (SV) cells isolated by collagenase digestion of minced inguinal WAT from C57BL/6 mice were plated onto a 6 cm tissue culture dish and cultured in 10% CO₂ at 37 °C. For white adipocyte differentiation, SV cells were expanded in growth media containing DMEM/F12 and 10% FBS. At confluence, cells were exposed to growth media supplemented with 5 μg/ml insulin, 1 μM dexamethasone, and 0.5 mM isobutylmethylxanthine for 48 h, and then maintained in growth media containing 5 μg/ml insulin for 6 days. Cells were fully differentiated on day 8.

Glucose production assay

Primary mouse hepatocytes were seeded into 24-well plates and pre-treated with 100 nM dexamethasone for 16 h. Then the medium was replaced with glucose production buffer consisting of glucose-free DMEM supplemented with 1 mM sodium pyruvate, 10 mM sodium lactate, and 0.25% BSA. After 24 h, the medium was collected for measuring glucose content by a colorimetric glucose assay kit (Applygen).

Real-time quantitative PCR (RT-qPCR)

Total RNA was extracted from mouse tissues or primary hepatocytes using Trizol regent. To quantify the transcript abundance of genes of interest, RT-qPCR was performed with a SYBR Green Premix Ex Taq (Takara) in an Applied Biosystems 7300 Real-Time PCR machine (Applied Biosystems). The primer sequences used for RT-qPCR were listed in Supplementary Table 1.

Western blotting and immunoprecipitation

Tissues or cells were homogenized in lysis buffer (Cell Signaling Technology). Blotted membrane was imaged with a LAS-4000 Super CCD Remote Control Science Imaging System (Fuji). Immunoprecipitation assays were performed by incubating protein lysates with indicated antibodies for 2 h and then with protein A/G-agarose beads (Santa Cruz) overnight at 4 °C. The immunoprecipitates were washed and eluted with SDS loading buffer. Then standard western blotting was followed. The antibodies were listed in Supplementary Table 2.

Nuclear and cytoplasmic protein extraction

Nuclear and cytoplasmic protein was extracted from primary mouse hepatocytes by means of commercial protocol and reagents (Thermo scientific) as previously described.
**Immunofluorescence staining**

HEK293T cells expressing HA-tagged FOXO1 were fixed for 20 min in 10% formalin, permeabilized in 0.1% Triton X100 for 5 min, washed with PBS, and blocked in 5% BSA for 1 h. Cells were then incubated with anti-HA antibody (1:200) overnight at 4°C and stained with FITC-labeled IgG (1:200, Jackson ImmunoResearch Laboratories). DAPI was added to stain cell nuclei. The cellular localization of HA-tagged FOXO1 was photographed and analyzed using a fluorescence microscope (Olympus BX51).

**Ubiquitylation assay**

For FOXO1 ubiquitylation analysis, HepG2 cells were transfected with plasmids of Flag-ubiquitin and HA-FOXO1 as indicated. Protease inhibitor MG132 and A-485 were added 4 h before harvest. 36 h after transfection, cells were collected and lysed in 1% SDS buffer. Immunoprecipitation of lysed proteins was performed by adding anti-HA antibody and ubiquitinated FOXO1 was detected by immunoblotting with anti-Flag antibody.

**Chromatin immunoprecipitation (ChIP)**

ChIP assay was performed by the ChIP kit (Millipore). Briefly, liver tissues from mice were incubated with 1% formaldehyde and homogenized in cell lysis buffer. The lysates were sonicated to yield chromatin fragments of 200–1000 bp. Chromatins were incubated and precipitated with antibody against FOXO1 or IgG. DNA pellets were analyzed by RT-qPCR by using primers directed to the glucose-6-phosphatase (G6Pc) promoter (Supplementary Table 3).

**Statistics**

Data were expressed as mean ± SEM. Comparisons were performed using ANOVA for multiple groups or the Student’s t test for two groups. Statistical significance was established at *P* < 0.05.

**Results**

**A-485 decreases body weight and fat mass in C57BL/6 mice**

To investigate the in vivo metabolic properties of A-485, 8-week-old C57BL/6 mice fed with NCD were intraperitoneally administrated with A-485 (20 mg·kg⁻¹·day⁻¹) for 1 week. A-485-administered mice displayed significantly lower body weight compared with vehicle-administered mice after treatment for 3 days (Fig. 1a). However, food intake was comparable between vehicle- and A-485-administered mice (Fig. S1a). No significant changes were observed for the oxygen consumption (V̇O₂), carbon dioxide (V̇CO₂) production, and respiratory exchange ratios (RER) in mice after A-485 administration (Fig. S1b–d). A-485 decreased total fat mass by ~14%, without affecting total lean mass (Fig. 1b, c). These results indicate that A-485-induced weight loss is attributable to decreased fat mass.

**A-485 treatment reduces hepatic glucose production in mice**

We further assessed the effects of A-485 on glucose and lipid metabolism in C57BL/6 mice. No differences were observed in plasma total cholesterol and triglyceride levels between two groups (Fig. S1e, f), with comparable random and 6 h fasting blood glucose levels (Fig. 1d, e). However, when fasting was prolonged to 16 h, fasting blood glucose level was decreased in A-485-administered mice compared with control mice (Fig. 1f), without significant difference in fasting serum insulin (Fig. 1g). GTT revealed a mild decrease in blood glucose levels of A-485-administered mice 15 and 30 min after glucose loading (Fig. 1h), while ITT showed comparable insulin sensitivity between two groups (Fig. 1i). Moreover, the blood glucose levels were lower in A-485-administered mice than those in control mice at 15 and 30 min during PTT (Fig. 1j). Hepatic G6Pc mRNA expression was dramatically decreased in A-485-administered mice (Fig. 1k), suggesting that A-485-suppressed hepatic glucose production contributes to decreased blood glucose level.

**Metabolic action of A-485 on mice fed with HFD**

To further investigate the therapeutic potential of A-485 in obese animals, mice fed with HFD for 14 weeks were treated with A-485 and their metabolic profiles were evaluated using the same protocol as described in NCD-fed mice. Consistently, A-485 treatment decreased body weight and total fat mass without altering total lean mass (Fig. 2a–c). Compared with HFD-fed mice, A-485-administered mice also exhibited lower fasting blood glucose level (Fig. 2d), without significant change in random blood glucose level (Fig. 2e). Like in NCD-fed mice, A-485 administration improved glucose tolerance in mice fed with HFD (Fig. 2f) and considerably decreased blood glucose levels in the whole process of PTT (Fig. 2g). Furthermore, the mRNA expression of hepatic G6Pc in HFD-fed mice was also dramatically reduced by A-485 treatment (Fig. 2h).

**Effect of A-485 on the expression of lipid metabolism-related genes in adipose tissue**

In parallel with A-485-mediated loss of fat mass, the drug did decrease the weight of epididymal white adipose tissue (eWAT) and inguinal white adipose tissue (IWAT) (Fig. 3a). As a result, the adipocyte size and gross size of WAT from A-485-administered mice were smaller than those of control mice, especially under HFD condition (Fig. 3b, c and Fig. S2a). We further detected the expressions of lipogenic genes in WAT of NCD- and
HFD-fed mice. A-485 remarkably decreased the mRNA expressions of key lipogenesis genes and transcription factors, including FASN (encoding fatty acid synthase, FAS), acetyl-CoA carboxylase (ACC), acyl-CoA desaturase 1 (SCD1), diacylglycerol O-acyltransferase 2 (DGAT2), carbohydrate response element-binding protein (ChREBP), and sterol response element-binding protein 1c (SREBP-1c) (Fig. 3d, e, and Fig. S2b, c). FAS and ACC protein expressions showed a similar result (Fig. 3f). However, there were no differences in the expressions of fatty acid oxidation-related genes such as carnitine palmitoyltransferase 1α, aconitate hydratase (ACO), medium-chain specific acyl-CoA dehydrogenase (MCAD), and very long-chain specific acyl-CoA dehydrogenase between two groups (Fig. 3g). Nor did the mRNA expression of classical brown adipocyte tissue marker gene uncoupling protein 1 (Fig. S2d). These results suggest that A-485 lowers fat mass mainly via repressing lipid biosynthesis in WAT, not by promoting lipid oxidation.

In addition, the mRNA levels of pan-adipocyte markers adiponectin, fatty acid-binding protein (FABP4), and lipoprotein lipase (LPL) were significantly decreased by A-485 in NCD- and HFD-fed mice (Fig. 3h, i, and Fig. S2e, f). Furthermore, the mRNA and protein expressions of peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha (C/EBPα), two master regulators of adipogenesis, were also robustly downregulated (Fig. 3j–l and Fig. S2g, h).

In fully differentiated primary adipocytes from mice, the expressions of lipogenesis-related genes were markedly suppressed after A-485 incubation for 24 h (Fig. S3a–e),
consistent with the in vivo results. These data suggest that the activity of CBP/p300 HAT domain is indispensable for maintaining normal adipogenesis and lipogenesis in WAT.

A-485 represses hepatic lipogenesis
CBP/p300 is involved in the regulation of hepatic lipogenic gene expression\textsuperscript{20–22}. Therefore, we explored whether this function of CBP/p300 relies on the activity of its HAT domain. Examination of liver sections revealed reduced number of lipid droplet in A-485-administered mice compared to control mice (Fig. 4a), with significant decreases in hepatic triglyceride (Fig. 4b, c) and total cholesterol (Fig. 4d, e) contents. Consistently, A-485 lowered the protein levels of FAS and ChREBP (Fig. 4f). In consistent with the results in WAT, A-485 did not change the expressions of fatty acid oxidation-related genes in liver of mice (Fig. 4g). We further examined the impact of A-485 treatment on lipid metabolism in primary mouse hepatocytes. As shown in Fig. 4h, in the presence of 100 nM insulin and 25 mM glucose, A-485 significantly decreased the mRNA expressions of key lipogenesis and cholesterol synthesis genes, including FASN, ACC, SCD1, and HMG-CoA synthase (HMGC51). Similarly, FAS, ACC, and ChREBP protein expressions exhibited remarkable decreases in A-485-treated hepatocytes (Fig. 4i). Though A-485 elevated the expression of fatty acid oxidation-related genes such as MCAD, ACO, CPT1a, and fibroblast growth factor 21 at basal status, the impact became weaker when high levels of insulin and glucose were present (Fig. 4j). These results indicate that A-485 reduces hepatic lipid accumulation mainly via repressing lipid biosynthesis.

A-485 inhibits gluconeogenesis in primary mouse hepatocytes
Glucagon promotes hepatic gluconeogenesis through the cAMP-PKA signaling pathway\textsuperscript{23}. In primary mouse hepatocytes, 8-Br-cAMP-stimulated glucose production was decreased after A-485 treatment for 24 h (Fig. 5a). cAMP-elicited mRNA expressions of three key gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK), G6Pc, and fructose 1,6-bisphosphatase (FBP) were significantly abolished after A-485 treatment for 8 h (Fig. 5b–d), but PEPCK protein expression failed to be changed in the presence or absence of cAMP (Fig. 5e). Once the incubation time was prolonged to 16 h, cAMP-induced protein expression of PEPCK was dramatically decreased by A-485 (Fig. 5f). We incubated primary mouse hepatocytes with A-485 and antidiabetic drug metformin. Interestingly, two drugs exhibited a synergistic inhibitory effect on hepatic glucose production and expressions of three key gluconeogenic enzymes (Fig. 5g–j).

Impact of A-485 on the expression of gluconeogenesis-related transcription factors
Phosphorylation of transcription factor CREB at Ser133 recruits coactivators such as CBP, p300, and TORC2 to cAMP response element (CRE) containing genes and
facilitates gluconeogenesis. It has been demonstrated that phosphorylation of CBP at Ser436 by metformin disrupts CBP binding to CREB, thereby repressing CREB-target gluconeogenic gene expressions and glucose production. Our recent study showed that metformin blocked TORC2 binding to CREB through activating AMPK and inhibiting cAMP-stimulated TORC2 dephosphorylation. Here A-485 did not significantly alter the phosphorylation of CREB or AMPK, nor did it impact TORC2 dephosphorylation in primary hepatocytes (Fig. 6a). Additionally, cAMP-mediated recruitment of CBP to CREB was not changed by A-485 while the recruitment of TORC2 was even enhanced (Fig. 6b). A-485 could not reverse the increased CRE luciferase activity stimulated by 8-Br-cAMP in HepG2 cells (Fig. 6c). cAMP-stimulated mRNA expression of PGC1α, a
gluconeogenic coactivator targeted by CREB27, was not
downregulated by A-485 (Fig. 6d). Therefore, we
investigated if other transcription factors were involved
in A-485-suppressed gluconeogenesis. No obvious dif-
fERENCE was observed for mRNA expression of hepato-
cyte nuclear factor 4-alpha (Fig. 6e) while cAMP-elicited
C/EBPα mRNA expression was attenuated after A-485
treatment (Fig. 6f). Though A-485 failed to alter FOXO1
mRNA expression (Fig. 6g), it antagonized cAMP-
elevated FOXO1 protein expression (Fig. 6h). C/EBPα
and PGC1α protein expressions exhibited a similar
result with their mRNA expressions in the presence of
8-Br-cAMP and A-485 (Fig. 6h). In line with this result,
hepatic protein levels of C/EBPα and FOXO1 were
lowered in A-485-administered mice compared with
control mice (Fig. 6i). The decreased occupancy of G6Pc
promoter with FOXO1 was observed in the liver isolated
from A-485-administered mice (Fig. 6j). These findings
suggest that FOXO1 and C/EBPα are involved in A-485-
mediated suppression of gluconeogenesis.

A-485 deacetylates hepatic FOXO1 and reduces its nuclear
abundance

PTM such as phosphorylation and acetylation is involved
in the regulation of FOXO1 activity through
primarily affecting its subcellular localization28. FOXO1
acetylation could be activated by CBP/p30029. Enhanced
acetylation promotes FOXO1 nuclear exclusion and
inhibits its transcriptional activity30,31. As a selective
inhibitor of CBP/p300 HAT activity, A-485 did induce the
deacetylation of FOXO1 in HepG2 cells (Fig. 7a). Unex-
pectedly, the protein abundance of FOXO1 was sig-
nificantly lowered in both cytoplasm and nuclear
extracted from primary mouse hepatocytes treated with
A-485 (Fig. 7b). FOXO1 was mainly localized in the
cytoplasm of 293T cells at basal status and cAMP
increased its abundance in nucleus, which was decreased by A-485 treatment (Fig. 7c).

**A-485 destabilizes hepatic FOXO1 protein**

A-485 treatment combined with protein synthesis inhibitor CHX dramatically shortened the half-life of endogenous FOXO1 in primary mouse hepatocytes (Fig. 7d, e). In addition, A-485-induced decrease in FOXO1 protein could be readily restored by the proteasome inhibitor MG132 (Fig. 7f, g), suggesting that inhibition of CBP/p300 HAT might target FOXO1 protein to proteasomal degradation. To address this question, HepG2 cells were transfected with HA-FOXO1 together with Flag-Ub expression plasmids. After treatment with MG132, HA-FOXO1 was examined for ubiquitination by Flag antibody. The ubiquitination level of FOXO1 was increased in cells exposed to A-485 (Fig. 7h). There are three types of enzymes involved in the process of ubiquitylation, including ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin-ligases (E3s), among which only E3s determine the target specificity of ubiquitylation reaction. COP1 has been
proved as an E3 ligase for FOXO1. In our study, the protein level of COP1 displayed no alteration in primary mouse hepatocytes after A-485 treatment (Fig. S4). However, the interaction between FOXO1 and COP1 was enhanced by A-485 (Fig. 7i). Collectively, these results suggest that A-485 destabilizes FOXO1 protein through promoting its ubiquitination.

**Discussion**

CBP/p300 plays a crucial role in the regulation of energy homeostasis through their acetyltransferase activity and their interactions with other transcription factors. Genome-wide association study and network analyses have revealed CBP as the most connected gene in protein–protein interactions in type 2 diabetes. In this current study, A-485, a recently identified first-in-class catalytic inhibitor for HAT domain of CBP/p300, markedly decreased body weight and fat mass as well as improved glucose metabolism in mice under either NCD or HFD condition. Lipogenesis in WAT and liver of mice was markedly suppressed and hepatic gluconeogenesis was decreased after A-485 administration. Thus, the HAT domain of CBP and p300 should be a sensitive drug target for the therapy of obesity-related diseases.

It was reported that CBP+/− mice exhibited lower body weight and fat mass compared with wild-type mice, along
with significant smaller size of adipocytes due to the inhibition of lipid accumulation\textsuperscript{36}. In another study, CH1 domain deletion of p300 (p300\textsuperscript{△CH1/△CH1}) and CBP (CBP\textsuperscript{△CH1/△CH1}) mice showed a similar metabolic phenotype, with reduced body weight and WAT\textsuperscript{13,36}. Interestingly, the specific inhibition of CBP/p300 HAT domain
by A-485 also led to a decrease in body weight and fat mass of mice, which is mainly attributed to the suppression of lipogenesis in WAT. These results indicate that maintaining fat reserves mediated by CBP/p300 is not only limited in transcription factor-binding CH1 domain, HAT domain is also involved. Though the domains of CBP/p300 are significantly shortened constructs and often considered in isolation, they are likely to coordinate to regulate the same process. The expressions of lipogenesis-related genes, pan-adipocyte markers, and master regulators of adipogenesis in WAT isolated from A-485-administered mice were all obviously lowered, suggesting that CBP/p300 HAT domain is indispensable for maintaining the function of WAT for energy storage and adipokine secretion.

In addition to WAT, inhibition of lipogenesis by A-485 was also found in hepatocytes. Previous studies indicate an intriguing connection between elevated acetylation of transcription factors such as FXR, SREBP-1c, and ChREBP, and increased lipogenic gene expressions, which provides a therapeutic strategy for nonalcoholic fatty liver disease. p300 has been proved to acetylate hepatic ChREBP on lys672 and increase its transcriptional activity, but increased acetylation mediated by p300 fails to affect ChREBP expression. Surprisingly, we found that A-485 directly decreased the expression of hepatic ChREBP. It is possible that the inhibition of another acetyltransferase CBP by A-485 explains the different result. In spite of the high sequence homology between CBP and p300, they may exert distinct effects on the same target. In the liver of CBP−/− mice, tissue triglyceride content was markedly reduced. Apparently, a reduction in hepatic lipogenic gene expression mediated by disrupting HAT domain of CBP/p300 contributes to decreased accumulation of lipid in liver.

Besides lipid metabolism, CBP and p300 are crucial regulators of glucose homeostasis. CBP is a CREB binding protein that interacts with the CREB KID domain. Glucagon stimulates hepatic gluconeogenesis via promoting the formation of transcriptional CREB–CBP–TORC2 complex on a CRE site of target genes. p300 overexpression led to glucose intolerance in mice, with increased expressions of PEPCK and G6Pase. In this current study, the decreased fasting blood glucose level in A-485-administered mice agreed well with the enhanced pyruvate tolerance and reduced hepatic G6pc expression, inconsistent with previously published results on CBP−/−/KID− and CBPΔCH1/ΔCH1 mice. Thus, it is CBP/p300 HAT domain that dominates its regulatory role in hepatic gluconeogenesis, which is further confirmed by in vitro experiments. In addition, metformin reduces gluconeogenic gene expression via inducing the phosphorylation of CBP and TORC2, triggering the dissociation of the CREB–CBP–TORC2 complex. Our study revealed a synergistic effect of A-485 and metformin on the inhibition of gluconeogenesis in primary hepatocytes. Moreover, the interaction of CREB–CBP–TORC2 complex was not altered by A-485. These results suggest that A-485 represses hepatic gluconeogenesis through a pathway distinct from metformin.

FOXOs belong to an evolutionarily conserved mammalian forkhead family of transcription factors, which regulate cell differentiation, metabolism, proliferation, and survival. Among FOXO family members, FOXO1 is not only tightly linked to hepatic gluconeogenesis, but also enhances lipogenesis and liver steatosis. Glucose is used for de novo lipogenesis in the liver, in which FOXO1 might be involved. In our study, A-485 decreased hepatic FOXO1 protein level. FOXO1 is traditionally regarded as an important component of insulin signaling cascades in suppressing gluconeogenesis. A recent study demonstrates a novel regulatory mechanism of FOXO1 by glucagon, which promotes FOXO1 stability and nuclear retention via cAMP/PKA-dependent phosphorylation of FOXO1 at Ser276. In this study, A-485 blocked cAMP-increased abundance of FOXO1 protein in nucleus and enhanced proteasome-mediated FOXO1 ubiquitination in primary hepatocytes. FOXO1 acetylation is activated by CBP at Lys242, Lys245, Lys262. In β cells, acetylated FOXO1 is retained in the nucleus and deacetylation of FOXO1 by SIRT1 accelerates FOXO1 degradation. However, a number of literatures hold the view that deacetylation of hepatic FOXO1 promotes its nuclear retention, thus increasing its activity for gluconeogenesis. In our study, A-485-mediated deacetylation of FOXO1 promoted its degradation in hepatocytes through ubiquitination, leading to the inhibition of gluconeogenesis.

In summary, A-485 disrupted lipogenesis in WAT and liver as well as suppressed hepatic gluconeogenesis in C57BL/6 mice, leading to the loss of body weight and improvement of glucose metabolism. A-485-mediated degradation of FOXO1 protein through a proteasome-dependent pathway is involved in the suppression of gluconeogenesis and lipogenesis. Therefore, the specific inhibition of CBP/p300 HAT will offer promise for a novel therapeutic approach of metabolic diseases.
Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-020-02960-6).

Received: 4 February 2020 Revised: 9 August 2020 Accepted: 25 August 2020
Published online: 11 September 2020

References
1. Zhao, S. M. et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004 (2010).
2. Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E. & Mann, M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 15, 536–550 (2014).
3. Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716 (2007).
4. Ye, J. Improving insulin sensitivity with HDAC inhibitor. Diabetes 62, 685–687 (2013).
5. Schiedel, M. & Conway, S. J. Small molecules as tools to study the chemical epigenetics of lysine acetylation. Curr. Opin. Biol. 45, 166–178 (2018).
6. Bedford, D. C., Kasper, L. H., Fukuyama, T. & Brindle, P. K. Target gene context accompanies this paper at (https://doi.org/10.1038/s41419-020-02960-6).
7. Dyson, H. J. & Wright, P. E. Role of intrinsic protein disorder in the function and biological control. EMBO J. 26, 2890–2903 (2007).
8. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503–533 (2001).
9. Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981–990 (2012).
10. Yao, W. L., Wang, T. X. & Huang, F. R. p300/CBP as a key nutritional sensor for hepatic energy homeostasis and liver fibrosis. Biomol. Res. Int. 2018, 8168791 (2018).
11. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503–533 (2001).
12. Kato, S., Ding, J., Pissilä, J., Jhala, U. S. & Dik, K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J. Biol. Chem. 283, 35464–35473 (2008).
13. Yang, Y. et al. Improved insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat. Genet. 30, 221–226 (2002).
14. Reinsløkær, K. et al. Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J. 26, 2880–2899 (2007).
15. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503–533 (2001).
16. Gross, D. N. et al. The role of FoxO1 in the regulation of metabolism. Oncogene 27, 2320–2336 (2008).
17. Zheng, W. et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 283, 10105–10117 (2008).
18. Yang, Y. et al. Improved insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat. Genet. 30, 221–226 (2002).
19. Reinsløkær, K. et al. Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J. 26, 2880–2899 (2007).
20. Gross, D. N. et al. The role of FoxO1 in the regulation of metabolism. Oncogene 27, 2320–2336 (2008).
21. Bricambert, J. et al. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of CREB-dependent hepatic steatosis in mice. J. Clin. Investig. 120, 4316–4331 (2010).
22. Kamper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10, 392–404 (2009).
23. Krebs, E. G. The albert lasker medical awards. Role of the cyclic AMP-dependent protein kinase in signal transduction. JAMA 262, 1815–1818 (1989).
24. Ko, S. H. et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109–1111 (2005).
25. Bo, L. et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635–646 (2009).
26. Li, X. et al. PPP1R3C mediates metformin-inhibited hepatic gluconeogenesis. Metabolism 98, 62–75 (2019).
27. Sharabi, K. et al. Selective chemical inhibition of PGC-1alpha gluconeogenic activity ameliorates type 2 diabetes. Cell 169, 148–160 (2017).
28. Vogt, P. K., Jiang, H. & Ack, M. Triple layer control phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell cycle 4, 908–913 (2005).
29. Daitoku, H. et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc. Natl Acad. Sci. USA 101, 10042–10047 (2004).
30. Qiang, L., Banks, A. S. & Accili, D. Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J. Biol. Chem. 285, 27396–27410 (2010).
31. Li, K. et al. Ets1-mediated acetylation of FoxO1 is critical for gluconeogenesis regulation during feed-fast cycles. Cell Rep. 26, 2998–3010 (2019).
32. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503–533 (2001).
33. Kato, S., Ding, J., Pissilä, J., Jhala, U. S. & Dik, K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J. Biol. Chem. 283, 35464–35473 (2008).
34. Yao, W. L., Wang, T. X. & Huang, F. R. p300/CBP as a key nutritional sensor for hepatic energy homeostasis and liver fibrosis. Biomol. Res. Int. 2018, 8168791 (2018).
35. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503–533 (2001).
36. Gross, D. N. et al. The role of FoxO1 in the regulation of metabolism. Oncogene 27, 2320–2336 (2008).
37. Zheng, W. et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 283, 10105–10117 (2008).
38. Hauser, M. et al. Integrative control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat. Commun. 5, 5190 (2014).
39. Guo, S. et al. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by fHHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J. Biol. Chem. 274, 17184–17192 (1999).
40. Onuma, H., Vander Kooi, B. T., Bouthead, J. N., Oesser, J. K. & O’Brien, R. M. Correlation between FOXO1a (fHHR) and FOXO3a (fHHR1) binding and the inhibition of basal glucose-6-phosphatase catalytic subunit gene transcription by insulins. Mol. Endocrinol. 20, 2831–2847 (2006).
41. Kitamura, Y. et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2, 153–163 (2005).
42. Matzuk, H. et al. Acetylation of FoxO1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl Acad. Sci. USA 102, 11278–11283 (2005).